A Phase 2 interventional study of Atacicept in IgA Nephropathy (IgAN) and Berger Disease, sponsored by Vera Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Vera Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Glomerulonephritis, IGA with a site in United States — 27 open to participants now, 39 under way, 18 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, this one is the 32nd largest by planned enrollment of the 69 interventional ones that give a count, is one of 11 that started in 2025, is one of 30 in phase 2, reaches primary completion later than 5 of the 38 other live ones, and was the 58th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 107 are open to participants now.
Browse Glomerulonephritis, IGA studies →27 of the 75 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Israel
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 24 · Phase 4 7
First in 1997; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 72 across the 69 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 75 have an industry lead sponsor. The 10 most frequent:
Vera Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Vera Therapeutics, Inc. has 4 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 75 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
This Phase 2 study is to explore the effectiveness, safety and tolerability of different dosing regimens of atacicept. Regimens include monthly and weekly dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Atacicept dose A administered subcutaneous (sc) injection monthly
Drug: Atacicept
Atacicept dose B administered subcutaneous (sc) injection monthly
Atacicept dose C administered subcutaneous (sc) injection monthly
Atacicept dose D administered subcutaneous (sc) injection weekly
Atacicept dose E administered subcutaneous (sc) injection weekly for 24 weeks, followed by monthly sc injections
Drug: Atacicept
Also known as: VT-001
Evaluate the effect of atacicept on Gd-IgA1 in patients with IgAN
Gd-IgA1 levels through Week 24
Time frame: Up to 24 weeks
To evaluate the safety and tolerability of atacicept at different dosing regimensT
Incidence of treatment emergent reported Adverse Events (AE)
Time frame: Baseline until end of study up to Week 24
To evaluate the effect of atacicept on serum immunoglobulins (IgA)
IgA levels through Week 24
Time frame: 24 Weeks
To evaluate the effect of atacicept on serum immunoglobulins (IgG)
IgG levels through Week 24
Time frame: 24 Weeks
To evaluate the effect of atacicept on serum immunoglobulins (IgM)
IgM levels through Week 24
Time frame: 24 Weeks
To evaluate serum PK of atacicept
Serum concentration of atacicept
Time frame: Baseline until end of study up to Week 24
Ran from May 2025 to primary completion in Sep 2026, 15 months.
Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TACI receptor-IgG Fc fragment fusion protein
Vera Therapeutics, Inc.